Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1537-1544

  Lancaster, Cynthia S ^a   Sprowl, Jason A ^a   Walker, Aisha L ^a   Hu, Shuiying ^a   Gibson, Alice A ^a   Sparreboom, Alex ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANION TRANSPORT PROTEIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ORGANIC ANION TRANSPORTER 2; OXALIPLATIN; PROTEIN SLCO1B3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CELL TRANSPORT; CELLULAR PARAMETERS; CELLULAR UPTAKE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; LIVER TO PLASMA RATIO; MALE; MAMMAL CELL; MODULATION; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; MALE; MICE; NEOPLASMS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PLATINUM;

EID: 84882236772     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0926     Document Type: Article

References (40)

1. Franke RM, Sparreboom A. Drug transporters: Recent advances and therapeutic applications. Clin Pharmacol Ther 2010;87:3-7.
2. Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: An exception or the rule? Nat Rev Drug Discov 2008;7: 205-20.
3. Van Winkle LJ. Biomembrane transport. San Diego, CA: Academic Press; 1999.
4. Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005;1:429-45.
5. Pressler H, Sissung TM, Venzon D, Price DK, Figg WD. Expression of OATP family members in hormone-related cancers: Potential markers of progression. PLoS One 2011;6:e20372.
6. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005;4:815-8.
7. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012;18:4433-40.
8. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3- fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008;36:695-701.
9. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001;120:1689-99.
10. Holbeck SL, Collins JM, Doroshow JH. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther 2010;9:1451-60.
11. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatininduced nephrotoxicity. Clin Pharmacol Ther 2009;86:396-402.
12. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res 2008; 14:3875-80.
13. Zaher H, Meyerzu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 2008;74:320-9.
14. Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks AP, et al. Neural computing in cancer drug development: Predicting mechanism of action. Science 1992;258:447-51.
15. Margiotta N, Marzano C, Gandin V, Osella D, Ravera M, Gabano E, et al. Revisiting [PtCl2(cis-1,4-DACH)]: An underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer. J Med Chem 2012;55:7182-92.
16. van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 2010;120:2942-52.
17. Stewart G. The emerging physiological roles of the SLC14A family of urea transporters. Br J Pharmacol 2011;164:1780-92.
18. Di Pasqua AJ, Goodisman J, Kerwood DJ, Toms BB, Dubowy RL, Dabrowiak JC. Role of carbonate in the cytotoxicity of carboplatin. Chem Res Toxicol 2007;20:896-904.
19. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, et al. Membrane transporters and channels: Role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64: 4294-301.
20. Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, et al. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 2008;7:3081-91.
21. Briz O, Serrano MA, Rebollo N, Hagenbuch B, Meier PJ, Koepsell H, et al. Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cisdiammine- bisursodeoxycholate-platinum(II) toward liver cells. Mol Pharmacol 2002;61:853-60.
22. Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, et al. Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 2008;260:163-9.
23. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, et al. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): Influence of protein expression on drug-drug interactions. J Med Chem 2012;55:4740-63.
24. Gale GR, Morris CR, Atkins LM, Smith AB. Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents. Cancer Res 1973;33:813-8.
25. Binks SP, Dobrota M. Kinetics and mechanism of uptake of platinumbased pharmaceuticals by the rat small intestine. Biochem Pharmacol 1990;40:1329-36.
26. Dobson PD, Lanthaler K, Oliver SG, Kell DB. Implications of the dominant role of transporters in drug uptake by cells. Curr Top Med Chem 2009;9:163-81.
27. Sprowl JA, Mikkelsen TS, Giovinazzo H, Sparreboom A. Contribution of tumoral and host solute carriers to clinical drug response. Drug Resist Updat 2012;15:5-20.
28. Liu JJ, Lu J, McKeage MJ. Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. Curr Cancer Drug Targets 2012;12:962-86.
29. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008;48:495-535.
30. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 2002;99:14298-302.
31. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 2009;15:553-60.
32. Litterst CL, Gram TE, Dedrick RL, Leroy AF, Guarino AM. Distribution and disposition of platinum following intravenous administration of cisdiamminedichloroplatinum (II) (NSC 119875) to dogs. Cancer Res 1976;36:2340-4.
33. Sharma RP, Edwards IR. cis-Platinum: Subcellular distribution and binding to cytosolic ligands. Biochem Pharmacol 1983;32:2665-9.
34. Junior AD, Mota LG, Nunan EA, Wainstein AJ, Wainstein AP, Leal AS, et al. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. Life Sci 2007;80:659-64.
35. Stewart DJ, Benjamin RS, Luna M, Feun L, Caprioli R, Seifert W, et al. Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol 1982;10:51-4.
36. Areberg J, Bjorkman S, Einarsson L, Frankenberg B, Lundqvist H, Mattsson S, et al. Gamma camera imaging of platinum in tumours and tissues of patients after administration of 191Pt-cisplatin. Acta Oncol 1999;38:221-8.
37. Marin JJ, Herrera MC, Palomero MF, Macias RI, Monte MJ, El-Mir MY, et al. Rat liver transport and biotransformation of a cytostatic complex of bis-cholylglycinate and platinum (II). J Hepatol 1998; 28:417-25.
38. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: The organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 2012;165:1260-87.
39. Iusuf D, van de Steeg E, Schinkel AH. Functions of OATP1A and 1B transporters in vivo: Insights from mouse models. Trends Pharmacol Sci 2012;33:100-8.
40. Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, de Waart DR, et al. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res 2008;14:8152-60.